Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Intern Emerg Med ; 2024 Mar 10.
Article En | MEDLINE | ID: mdl-38461469

Eosinophilic colitis (EC) is the rarest among primary eosinophilic gastrointestinal disorders (EGID). EC is underdiagnosed due to its blurred and proteiform clinical manifestations. To explore the clinical and atopic characteristic of EC adult patients, the diagnostic delay, and relapse-associated factors, by comparison with patients with eosinophilic esophagitis (EoE) and irritable bowel syndrome (IBS). EC patients followed-up at four clinics were included, and clinical, histopathological, and laboratory data were retrieved. As control groups, age-matched patients with EoE and IBS were recruited. Allergy tests included skin prick test and serum specific IgE. Diagnostic delay was assessed. Overall, data from 73 patients were retrieved, including 40 with EC (median age 39 years IQR 22.5-59, F:M 2.1:1), 12 with EoE (F:M ratio: 1:5), and 21 with IBS (F:M ratio: 1:0.9). The most common features in EC patients were female sex (67.5%), atopy (77.5%), abdominal pain/distention (70%), diarrhoea (77.5%), and faecal calprotectin elevation (22.5%). Blood eosinophils were elevated in EoE, but not in EC (p < 0.001), while ECP did not differ across the three groups (p = 0.4). The frequency of allergen sensitization reached 25% of patients. Several frequent pan-allergens for this region were present. The overall diagnostic delay was 10 months (IQR 4-15). Factors contributing to a greater diagnostic delay were atopy, weight loss, and a previous misdiagnosis. EC is mostly a diagnosis of exclusion, burdened by a substantial diagnostic delay. In female patients the presence of allergen sensitization, abdominal symptoms and faecal calprotectin elevation should raise the suspicion of EC.

2.
Pediatr Blood Cancer ; 60(8): E52-4, 2013 Aug.
Article En | MEDLINE | ID: mdl-23441089

Essential thrombocythemia (ET) is extremely rare in the pediatric population. In most patients no molecular abnormality can be found, with about 40% of pediatric patients harboring a JAK2 V617F mutation. Another recurrent mutation, involving a W to L or K transversion at MPL codon 515, has been reported in about 3-8% of adult ET patients. Herein we describe this mutation in a pediatric patient.


Mutation, Missense , Receptors, Thrombopoietin/genetics , Thrombocythemia, Essential/genetics , Adult , Amino Acid Substitution , Child, Preschool , Humans , Janus Kinase 2/genetics , Janus Kinase 2/metabolism , Male , Receptors, Thrombopoietin/metabolism , Thrombocythemia, Essential/metabolism , Thrombocythemia, Essential/pathology
3.
J Pediatr Hematol Oncol ; 28(3): 177-81, 2006 Mar.
Article En | MEDLINE | ID: mdl-16679945

Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare complication of cancer chemotherapy. We have recently observed two cases occurred simultaneously in children receiving different chemotherapy regimens, for hepatoblastoma and acute lymphoblastic leukaemia, respectively. Both children presented with altered mental status, severe visual disturbances, headache, seizures, backpain and hypertension. Magnetic resonance imaging showed cortical and subcortical lesions especially in the occipital and parietal regions, strongly consistent with RPLS. Both patients completely recovered from their neuropsychologic deficits in about ten days only with anticonvulsant and antihypertensive therapy, and chemotherapy regimen was promptly restarted according to the planned protocol, without any neuropsychological sequela. A mild left midriasis was the only neurologic defect that persisted in the patient with acute lymphoblastic leukemia.


Antineoplastic Agents/adverse effects , Brain Diseases/etiology , Hepatoblastoma/complications , Liver Neoplasms/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Adolescent , Brain Diseases/pathology , Brain Diseases/physiopathology , Child , Hepatoblastoma/drug therapy , Humans , Liver Neoplasms/drug therapy , Magnetic Resonance Imaging , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
...